{"id":"NCT02276612","sponsor":"Gilead Sciences","briefTitle":"Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents","officialTitle":"A Phase 2/3, Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-12-03","primaryCompletion":"2016-11-10","completion":"2017-10-23","firstPosted":"2014-10-28","resultsPosted":"2018-02-22","lastUpdate":"2018-11-19"},"enrollment":60,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV"],"interventions":[{"type":"DRUG","name":"E/C/F/TAF","otherNames":["Genvoya®"]}],"arms":[{"label":"E/C/F/TAF","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected virologically suppressed adolescents 12 to \\< 18 years of age.","primaryOutcome":{"measure":"Incidence of Treatment-Emergent Serious Adverse Events","timeFrame":"Up to Week 48","effectByArm":[{"arm":"E/C/F/TAF (12 - 17 Years of Age)","deltaMin":4,"sd":null},{"arm":"E/C/F/TAF (≥ 18 Years of Age)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":3},"locations":{"siteCount":7,"countries":["United States","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":50},"commonTop":["Upper respiratory tract infection","Cough","Diarrhoea","Vomiting","Headache"]}}